Brussels, 07/06/2006 (Agence Europe) - The European Medicines Agency (EMEA) has adopted a positive opinion on the use of Prozac (fluoxetine) for the treatment of children and teenagers suffering from depression who do not respond to psychological therapy. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of using Prozac outweigh its potential risks but that the marketing authorisation holder, US company Eli Lilly, 'should carry out additional...